Evidence map›Paper›PMID 40804570›Full record

ArticleAnnals of surgical oncology2025

Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma.

Yawen Dong, Vanja Podrascanin, Zhihao Li, Jonas Santol, Markus Ammann, Lionel A Kankeu Fonkoua, Rondell P Graham, Caitlin B Conboy, Nguyen H Tran, Susanne G Warner and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yawen DongDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
Vanja PodrascaninDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
Zhihao LiDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
Jonas SantolDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
Markus AmmannDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
Lionel A Kankeu FonkouaDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Rondell P GrahamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Caitlin B ConboyDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Nguyen H TranDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Susanne G WarnerDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
Rory L SmootDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
Patrick P StarlingerDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic Rochester, Rochester, MN, USA. starlinger.patrick@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGemcitabine, cisplatin, and durvalumab (GCD) have previously demonstrated favorable outcomes in advanced cholangiocarcinoma (CCA), leading to their approval as first-line therapy. This study evaluates the feasibility of GCD for borderline resectable CCA in the neoadjuvant setting. PATIENTS AND

methodsPatients with borderline resectable CCA receiving neoadjuvant GCD between April 2022 and July 2024 were included. Treatment response (radiologic and pathologic), tolerability, postoperative morbidity, and survival outcomes were assessed.

resultsOf 106 screened patients, 26 with anatomically or biologically borderline resectable disease received neoadjuvant GCD, with 12 proceeding to surgery (conversion rate: 46.2%). Extended resections were performed with extrahepatic bile duct resection (33.3%) and vascular reconstruction (25%). Tumor size reduction was observed in all resected patients, with RECIST showing stable disease in 83.3% and partial response in 16.7%. Pathologic response varied with no/minimal response in 41.7%, partial regression in 50.0%, and one complete response (8.3%). Postoperative morbidity (≥ grade III) was 50.0%, with 0% 90-day mortality. As of April 2025, 91.7% of resected patients were alive, although three developed recurrences (RFS: 5.5, 5.7, 6.8 months). Overall survival (OS) was significantly longer in resected versus non-resected patients (median OS: not reached versus 20.8 months, p = 0.047).

conclusionsOur study indicates that neoadjuvant GCD is safe and well tolerated prior to extensive liver resection for borderline resectable CCA. A conversion rate of 46.2% suggests that GCD might be a promising treatment for patients with anatomically and biologically borderline resectable CCA. Heterogeneity of pathologic response rate highlights the need for biomarker-directed correlative studies in future investigations.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsCholangiocarcinomaCisplatinGemcitabineAgedAntibodies, MonoclonalBiliary Tract Surgical ProceduresFeasibility StudiesFemaleHepatectomyHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm GradingAntibodies, MonoclonalCisplatindurvalumabGemcitabineBorderline resectableConversion rateImmune checkpoint inhibitorNeoadjuvant therapyPathologic responseReal world

Identifiers

PMID40804570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.